ABPI, Serious Fraud Office explain enforcement policy on UK Bribery Act and industry code breaches
This article was originally published in SRA
Ahead of the UK Bribery Act coming into effect on 1 July, the Association of the British Pharmaceutical Industry and the Serious Fraud Office have issued clarification on which of the two parties is likely to lead on enforcement in cases where a breach of the ABPI's code of practice is also a potential breach of the new legislation1,2.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.